A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 4, 2009, Pages 777-783

  Ramanathan, Ramesh K ^a,g   Belani, Chandra P ^a   Singh, Deepti A ^b   Tanaka, Michael ^c   Lenz, Heinz Josef ^d   Yen, Yun ^e   Kindler, Hedy L ^b   Iqbal, Syma ^d   Longmate, Jeff ^e   MacK, Philip C ^c   Lurje, Georg ^d   Gandour Edwards, Regina ^c   Dancey, Janet ^f   Gandara, David R ^c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g Scottsdale Clinical Research Institute   (United States)

Author keywords

Biliary tree cancer; Hepatocellular cancer; Lapatinib; Phase II study

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; LAPATINIB; LOPERAMIDE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CANCER; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENOTYPE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOCALCEMIA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; OVERALL SURVIVAL; PHARMACOGENOMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; BILIARY TRACT NEOPLASMS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; QUINAZOLINES; SURVIVAL ANALYSIS;

EID: 68149164263     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-0927-7     Document Type: Article

References (30)

1. HB El-Serag KL Rudolph 2007 Hepatocellular carcinoma: epidemiology and molecular carcinogenesis Gastroenterology 132 2557 2576
2. SR Alberts GJ Gores GP Kim 2007 Treatment options for hepatobiliary and pancreatic cancer Mayo Clin Proc 82 628 637
3. M Shimoda K Kubota 2007 Multi-disciplinary treatment for cholangiocellular carcinoma World J Gastroenterol 13 1500 1504
4. Bartlett D, Ramanathan RK, Ben-Joseph E (2008) Gallbladder and bilary cancers. In: Devita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 8th edn. Lippincott, Philadelphia
5. C Berasain J Castillo J Prieto 2007 New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system Liver Int 27 174 185
6. T Bekaii-Saab N Williams C Plass 2006 A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma BMC Cancer 6 278
7. JH Yoon GY Gwak HS Lee 2004 Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells J Hepatol 41 808 814
8. A Sirica 2005 Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy Hepatology 41 5 15
9. PA Philip MR Mahoney C Allmer 2005 Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer J Clin Oncol 23 6657 6663
10. MB Thomas R Chadha K Glover 2007 Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma Cancer 110 1059 1067
11. PA Philip MR Mahoney C Allmer 2006 Phase II study of erlotinib in patients with advanced biliary cancer J Clin Oncol 24 3069 3074
12. A Reid L Vidal H Shaw 2007 Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu) Eur J Cancer 43 481 489
13. P Therasse SG Arbuck EA Eisenhauer 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216 (Pubitemid 30099779)
14. R Simon 1989 Optimal two-stage design for phase II clinical trials Control Clin Trials 10 1 10
15. O Gautschi B Huegli A Ziegler 2007 Origin and prognostic value of circulating KRAS mutations in lung cancer patients Cancer Lett 254 265 273
16. W Zhang DJ Park B Lu 2005 Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation Clin Cancer Res 11 600 605
17. M Matsuo H Sakurai I Saiki 2003 ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model Mol Cancer Ther 2 557 561
18. E Schiffer C Housset W Cacheux 2005 Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis Hepatology 41 307 314
19. AX Zhu K Stuart LS Blaszkowsky 2007 Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma Cancer 110 581 589
20. JM Llovet S Ricci v Mazzaferro SHARP Investigators Study Group 2008 Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378 390
21. R Peréz-Soler L Saltz 2005 Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23 5235 5246
22. CE Geyer J Forster D Lindquist 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733 2743
23. MF Press RS Finn D Cameron 2008 HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer Clin Cancer Res 14 7861 7870
24. Van Cutsem E, Lang I, D'haens G et al (2008) KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol 26(May 20 suppl), abstr 2
25. INK4Amethylation in hepatocellular carcinomas in workers exposed to vinyl chloride Br J Cancer 84 982 989 (Pubitemid 32385844)
26. R Mayoral A Fernandez-Martinez L Bosca 2005 Prostaglandin E2 promotes migration and adhesion in hepatocellular carcinoma cells Carcinogenesis 26 753 761
27. C Mitchell M Nivison LF Jackson 2005 Heparin-binding epidermal growth factor-like growth factor links hepatocyte priming with cell cycle progression during liver regeneration J Biol Chem 280 2562 2568
28. Buerger H, Gebhardt F, Schmidt H et al (2000) Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res 60:854-857
29. F Gebhardt KS Zanker B Brandt 1999 Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1 J Biol Chem 274 13176 13180
30. JM Llovet AM Di Bisceglie J Bruix 2008 Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 698 711